Latest Ratios: P/E Ratio -0.5x · EV/EBITDA N/A · ROE -35.3%. (2011–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $2M | — | — | — | — | — | — | — | — | — | — |
| Enterprise Value | $-8012665 | — | — | — | — | — | — | — | — | — | — |
| P/E Ratio → | -0.53 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 16.37 | — | — | — | — | — | — | — | — | — | — |
| P/B Ratio | 0.13 | — | — | — | — | — | — | — | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 96.5% | 96.5% | 100.0% | 100.0% | 100.0% | — | 85.1% | 84.4% | 77.6% | 77.4% | 100.0% |
| Operating Margin | -8761.1% | -8761.1% | -13840.4% | -4792.2% | -765.3% | — | -977.9% | -882.4% | -766.3% | -911.9% | -2605.7% |
| Net Profit Margin | -1727.8% | -1727.8% | -13459.6% | -4664.6% | -763.2% | — | -852.0% | -861.7% | -756.1% | -908.9% | -2601.1% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -35.3% | -35.3% | -155.0% | -75.8% | -33.0% | -51.1% | -59.5% | -65.9% | -65.1% | -61.7% | -69.6% |
| ROA | -23.7% | -23.7% | -110.1% | -64.4% | -31.3% | -49.2% | -54.2% | -58.9% | -58.5% | -56.2% | -63.7% |
| ROIC | -854.0% | -854.0% | -576.2% | -479.2% | -310.3% | -2279.9% | — | -6007.5% | -11232.8% | — | -32202.5% |
| ROCE | -163.8% | -163.8% | -142.8% | -73.0% | -32.3% | -51.1% | -67.6% | -66.5% | -65.1% | -61.1% | -69.1% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.09 | 0.09 | 0.39 | 0.12 | 0.07 | — | — | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.99 | -0.42 | -0.88 | -0.88 | -0.95 | -1.03 | -1.00 | -0.98 | -1.01 | -1.00 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -247.60 | -247.60 | — | — | — | — | — | — | — | — | — |
Net cash position: cash ($11M) exceeds total debt ($942000)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.25 | 3.25 | 2.12 | 4.64 | 21.35 | 53.26 | 15.65 | 10.32 | 10.04 | 10.83 | 14.18 |
| Quick Ratio | 3.25 | 3.25 | 1.96 | 4.64 | 21.35 | 53.26 | 15.65 | 10.19 | 9.86 | 10.74 | 14.10 |
| Cash Ratio | 3.03 | 3.03 | 1.56 | 4.36 | 20.73 | 51.82 | 15.11 | 9.76 | 9.39 | 10.44 | 13.83 |
| Asset Turnover | — | 0.01 | 0.02 | 0.02 | 0.05 | — | 0.08 | 0.08 | 0.09 | 0.06 | 0.02 |
| Inventory Turnover | — | — | — | — | — | — | — | 0.98 | 1.22 | 1.74 | — |
| Days Sales Outstanding | — | 76.04 | 110.50 | 149.95 | — | — | 18.45 | 65.89 | 81.52 | 55.83 | 63.75 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | — | — | — | — | — | — | — | — | — | — |
| Total Shareholder Yield | 0.0% | — | — | — | — | — | — | — | — | — | — |
| Shares Outstanding | — | $1M | $762076 | $726085 | $725299 | $575166 | $539817 | $480749 | $446849 | $407345 | $375238 |
Binary clinical trial failure
According to recent market data, VIVS trades at a price-to-sales multiple of 18.65, a figure that appears disconnected from fundamental performance and suggests investors are pricing the equity as a speculative binary option rather than a business with predictable, recurring revenue streams or tangible asset backing.
The elevated P/S ratio relative to the company's negligible revenue base indicates that the market is assigning value to the potential of the FXR314 pipeline rather than current operations. Investors should monitor whether this valuation premium can be sustained as the company approaches critical clinical milestones, as any negative data could lead to a rapid compression of these multiples.
Based on reported figures, VIVS has consistently generated negative ROIC, with the most recent quarterly data showing a -2.3% return, which underscores the company's inability to deploy invested capital into projects that generate economic value above the cost of the capital itself.
The persistent decay in returns on invested capital suggests that the company's pivot toward drug development has yet to yield a productive asset base. This trend warrants further investigation into whether the current R&D spend is creating long-term intellectual property or merely funding the ongoing operational burn.
As reported in financial statements, the company's efficiency metrics are highly erratic, with DSO figures reaching as high as 1904 in 2026Q3, suggesting that the firm struggles to convert its project-based research collaborations into timely cash inflows, thereby exacerbating its already precarious liquidity position.
The extreme volatility in the cash conversion cycle reflects a business model that is not yet optimized for operational efficiency. This lack of predictability in working capital management suggests that the company remains highly dependent on external financing rather than internal cash generation to fund its daily operations.
Based on the latest quarterly filings, the current ratio has fluctuated significantly, settling at 2.44 in 2026Q3, yet this metric masks the underlying reality that the absolute cash balance is insufficient to support the high-cost, late-stage clinical trials required for the company's lead drug candidate.
While the current ratio may appear adequate on the surface, the rapid depletion of cash reserves indicates that the company's liquidity position is highly vulnerable to unforeseen clinical delays. Investors should monitor the cash runway closely, as the current burn rate suggests an imminent need for dilutive capital raises.
As evidenced by the reported 100% gross margin in recent quarters, this specific ratio is frequently misapplied to VIVS, as it obscures the massive, non-capitalized R&D expenditures that are essential to the company's survival and do not appear in the cost of goods sold calculation.
Analysts should instead focus on the burn-to-revenue ratio or operating cash flow, as the gross margin provides no insight into the company's ability to achieve profitability. Relying on gross margin in a pre-revenue biotech context creates a false sense of efficiency that ignores the structural reality of the firm's high fixed-cost base.
Includes 30+ ratios · 14 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying VIVS stock.
VivoSim Labs, Inc.'s current P/E ratio is -0.5x. This places it at the 50th percentile of its historical range.
VivoSim Labs, Inc.'s return on equity (ROE) is -35.3%. The historical average is -71.2%.
Based on historical data, VivoSim Labs, Inc. is trading at a P/E of -0.5x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
VivoSim Labs, Inc. has 96.5% gross margin and -8761.1% operating margin.